Publicación:
Secondary CV Prevention in South America in a Community Setting : The PURE Study

Página de artículo simple
dc.contributor.authorAvezum, Alvarospa
dc.contributor.authorOliveira, Gustavospa
dc.contributor.authorLanas, Fernandospa
dc.contributor.authorLopez-Jaramillo, Patriciospa
dc.contributor.authorDiaz, Rafaelspa
dc.contributor.authorMiranda, J. Jaimespa
dc.contributor.authorSeron, Pamelaspa
dc.contributor.authorCamacho López, Paul Anthonyspa
dc.contributor.authorOrlandini, Andresspa
dc.contributor.authorOrtiz, Antonio Bernabespa
dc.contributor.authorMattos, Antônio Cordeirospa
dc.contributor.authorIslam, Shofiqulspa
dc.contributor.authorRangarajan, Sumathyspa
dc.contributor.authorTeo, Koonspa
dc.contributor.authorYusuf, Salimspa
dc.date.accessioned2019-07-17T19:16:12Zspa
dc.date.available2019-07-17T19:16:12Zspa
dc.date.issued2017-12spa
dc.description9 p.spa
dc.description.abstractBackground Despite the availability of evidence-based therapies, there is no information on the use of medications for the secondary prevention of cardiovascular disease in urban and rural community settings in South America. Objectives This study sought to assess the use, and its predictors, of effective secondary prevention therapies in individuals with a history of coronary heart disease (CHD) or stroke. Methods In the PURE (Prospective Urban Rural Epidemiological) study, we enrolled 24,713 individuals from South America ages 35 to 70 years from 97 rural and urban communities in Argentina, Brazil, Chile, and Colombia. We assessed the use of proven therapies with standardized questionnaires. We report estimates of drug use at national, community, and individual levels and the independent predictors of their utilization through a multivariable analysis model. Results Of 24,713 individuals, 910 had a self-reported CHD event (at a median of 5 years earlier) and 407 had stroke (6 years earlier). The proportions of individuals with CHD who received antiplatelet medications (30.1%), beta-blockers (34.2%), angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers (36.0%), or statins (18.0%) were low; with even lower proportions among stroke patients (antiplatelets 24.3%, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 37.6%, statins 9.8%). A substantial proportion of patients did not receive any proven therapy (CHD 31%, stroke 54%). A minority of patients received either all 4 (4.1%) or 3 proven therapies (3.3%). Male sex, age >60 years, better education, more wealth, urban location, diabetes, and obesity were associated with higher rates of medication use. In a multivariable model, markers of wealth had the largest impact in secondary prevention. Conclusions There are large gaps in the use of proven medications for secondary prevention of cardiovascular disease in South America. Strategies to improve the sustained use of these medications will likely reduce cardiovascular disease burden substantially.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.1016/j.gheart.2016.06.001eng
dc.identifier.issn2211-8160spa
dc.identifier.urihttps://repositorio.udes.edu.co/handle/001/3415spa
dc.language.isoengspa
dc.relation.ispartofGlobal Hearteng
dc.rightsDerechos Reservados - Global Heart, 2017spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.sourcehttps://www.sciencedirect.com/science/article/pii/S2211816016307001?via%3Dihubeng
dc.subject.proposalSecondary CV Preventioneng
dc.subject.proposalSouth Americaeng
dc.titleSecondary CV Prevention in South America in a Community Setting : The PURE Studyeng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Secondary CV Prevention in South America in a Community Setting. The PURE Study.pdf
Tamaño:
246.37 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Paquete de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
59 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
AGBBA. Artículos de Investigación